Drug-Induced Pancreatitis Incidence, Management and Prevention

被引:152
作者
Balani, Anil R. [1 ,2 ]
Grendell, James H. [1 ,2 ]
机构
[1] Winthrop Univ Hosp, Div Gastroenterol Hepatol & Nutr, New York, NY 11501 USA
[2] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
关键词
D O I
10.2165/00002018-200831100-00002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Drugs are a relatively rare cause of acute pancreatitis, with an estimated incidence of 0.1-2%. Many drugs have been Suspected of causing pancreatitis, but the true incidence is not known as the evidence is derived mainly from random case reports. Case reports with the strongest evidence are those that clearly diagnose pancreatitis and exclude common aetiologics, provide the dose and time interval between the start of treatment with the suspected drug and the development of pancreatitis, document response to withdrawal of the drug, and demonstrate recurrent pancreatitis upon rechallenge with the drug. Few data exist on the mechanisms of drug-induced pancreatitis. Certain subpopulations such as children, women, the elderly and patients with advanced HIV infection or inflammatory bowel disease may be at higher risk. The diagnosis of drug-induced pancreatitis is often challenging because there are no unique clinical characteristics to distinguish drugs from other causes of pancreatitis. The majority of cases are mild, but severe and even fatal cases may occur, thus making identification of the offending agent critical. Management of drug-induced acute pancreatitis requires withdrawal of the offending agent and supportive care. Prevention of drug-induced pancreatitis requires an up-to-date knowledge of drugs that have the strongest evidence linking their use to the development of pancreatitis as well as the proposed mechanisms through which they may cause the reaction. In this papaer, the epidemiology, diagnosis, management and prevention of drug-induced pancreatitis is reviewed. Drugs and classes of drugs strongly implicated as causing acute pancreatitis, based on well documented case reports, are discussed in detail.
引用
收藏
页码:823 / 837
页数:15
相关论文
共 243 条
[1]   PANCREATITIS AND RHABDOMYOLYSIS ASSOCIATED WITH LOVASTATIN-GEMFIBROZIL THERAPY [J].
ABDULGHAFFAR, NUAMA ;
ELSONBATY, MR .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1995, 21 (04) :340-341
[2]   Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis [J].
Alagozlu, Hakan ;
Cindoruk, Mehmet ;
Unal, Selahattin .
CLINICAL DRUG INVESTIGATION, 2006, 26 (05) :297-302
[3]  
ALTMAN AJ, 1982, CANCER, V49, P1384, DOI 10.1002/1097-0142(19820401)49:7<1384::AID-CNCR2820490714>3.0.CO
[4]  
2-6
[5]  
Alvarez OA, 2000, MED PEDIATR ONCOL, V34, P200, DOI 10.1002/(SICI)1096-911X(200003)34:3<200::AID-MPO7>3.0.CO
[6]  
2-T
[7]  
Anagnostopoulos George K, 2003, JOP, V4, P129
[8]   Fulminant pancreatitis associated with ramipril therapy [J].
Anagnostopoulos, GK ;
Kostopoulos, P ;
Tsiakos, S ;
Margantinis, G ;
Arvanitidis, D .
PANCREAS, 2003, 27 (03) :278-279
[9]   Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999 [J].
Andersen, V ;
Sonne, J ;
Andersen, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (6-7) :517-521
[10]  
Antonopoulos S, 2005, J PANCREAS, V6, P264